A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-treat ovarian cancer, a phase I/II clinical trial led by Dana-Farber Cancer Institute researchers … Read more
A vaccine derived from a patient’s tumor cells, which enhances T-cell targeting of cancer cells, has shown promise against ovarian cancer.
This outcome of a phase 1 clinical trial was reported at the Society of Gynecologic Oncology’s 2018 Annual Meeting … Read more
Despite showing an interest in clinical trials and biobanking, underserved populations appear to be unclear on how to learn about them, while community physicians reported lacking appropriate information to give them, according to data to be presented at the American … Read more
“Fighting my cancer as much as possible” is why many patients participate in early stage clinical trials, according to research presented at the TAT (Targeted Anticancer Therapies) International Congress 2018 in Paris, France.
“The importance of early stage trials is … Read more
By: Deborah Zajchowski, PhD – Scientific Director, The Clearity Foundation
In the past three years, new hope has come to many women with ovarian cancer because of four new drugs that were approved for the treatment of this disease. These … Read more
To date, trials testing the use of immunotherapy in the treatment of ovarian cancer yielded disappointing results. However, researchers are not giving up. Instead, they’re investigating to see if immunotherapy drugs – such as PD1 and PDL-1 inhibitors – can … Read more
When Wendy Ericsson learned she had uterine cancer in December 2012 she went looking for information, but didn’t find much out there about her disease.
Through her doctor, she was directed to the Foundation for Women’s Cancer (FWC).
“There’s a … Read more
By: Susan Gubar
As an ovarian cancer patient whose life is being extended by a clinical trial, I was delighted to learn this summer that research on gynecological cancers is undergoing an unusually productive period. But I’m dismayed that at … Read more
Cancer patients struggle to understand what is involved in a clinical trial, even when they have participated in them. In a survey of 1090 adult cancer patients, more than half did not understand the concepts of clinical equipoise or randomization.… Read more
With the arrival of two revolutionary treatment strategies, immunotherapy and personalized medicine, cancer researchers have found new hope — and a problem that is perhaps unprecedented in medical research.
There are too many experimental cancer drugs in too many clinical … Read more
For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are … Read more
Technology developed at Western University and Lawson Health Research Institute can provide a new window into whether or not patients are responding to treatment for advanced ovarian cancer. A multi-centre clinical trial has demonstrated that CT Perfusion, which measures blood … Read more
UConn Health is beginning to recruit patients for the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. The goal: to prevent an often deadly relapse of the disease in women diagnosed at advanced stages.
The pioneering injectable vaccine OncoImmunome … Read more
Fewer than half of women diagnosed with ovarian cancer live for five years or more. Sarah Adams, MD, a cancer doctor at the UNM Comprehensive Cancer Center, hopes a new therapy that delivers a one-two punch to cancer cells will … Read more
A meta-analysis of 346 phase I clinical trials involving more than 13,000 patients found that patients whose treatment was selected based on the molecular characteristics of their tumor had significantly better outcomes. The study was featured in a press briefing … Read more
Clinical trials may be a good treatment option for some patients with cancer, but these trials can be difficult to understand. Dr. Susan Gubar, a retired professor of English at Indiana University and author of Memoir of a Debulked Woman, … Read more
Mary Pazdur had exhausted the usual drugs for ovarian cancer, and with her tumors growing and her condition deteriorating, her last hope seemed to be an experimental compound that had yet to be approved by federal regulators.
So she appealed … Read more